[go: up one dir, main page]

CN111212903A - 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 - Google Patents

具有自杀基因开关的靶向人间皮素的工程化免疫细胞 Download PDF

Info

Publication number
CN111212903A
CN111212903A CN201880062886.9A CN201880062886A CN111212903A CN 111212903 A CN111212903 A CN 111212903A CN 201880062886 A CN201880062886 A CN 201880062886A CN 111212903 A CN111212903 A CN 111212903A
Authority
CN
China
Prior art keywords
cell
car
cells
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880062886.9A
Other languages
English (en)
Inventor
曹卫
张华�
张永亮
江鹏斐
刘丽萍
杨春辉
石欢
马玲
何佳平
马安云
沈连军
王欣欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genxi Biotechnology Shanghai Co Ltd
Original Assignee
Genxi Biotechnology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genxi Biotechnology Shanghai Co Ltd filed Critical Genxi Biotechnology Shanghai Co Ltd
Publication of CN111212903A publication Critical patent/CN111212903A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

提供了一种靶向间皮素的嵌合抗原受体T细胞，该细胞的CAR结构中包含细胞自杀元件，并且细胞中的PD1基因表达是被沉默的。还提供了含有该细胞的制剂、用途以及用于制备细胞的试剂盒。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201880062886.9A 2017-09-30 2018-09-30 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 Pending CN111212903A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710916606.3A CN109593721B (zh) 2017-09-30 2017-09-30 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
CN2017109166063 2017-09-30
PCT/CN2018/109134 WO2019063018A1 (zh) 2017-09-30 2018-09-30 具有自杀基因开关的靶向人间皮素的工程化免疫细胞

Publications (1)

Publication Number Publication Date
CN111212903A true CN111212903A (zh) 2020-05-29

Family

ID=65900638

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710916606.3A Expired - Fee Related CN109593721B (zh) 2017-09-30 2017-09-30 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
CN201880062886.9A Pending CN111212903A (zh) 2017-09-30 2018-09-30 具有自杀基因开关的靶向人间皮素的工程化免疫细胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710916606.3A Expired - Fee Related CN109593721B (zh) 2017-09-30 2017-09-30 具有自杀基因开关的靶向人间皮素的工程化免疫细胞

Country Status (2)

Country Link
CN (2) CN109593721B (zh)
WO (1) WO2019063018A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116218914A (zh) * 2023-03-28 2023-06-06 武汉大学 一种构建肿瘤复发动物模型的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
US20230144237A1 (en) * 2019-04-22 2023-05-11 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
CA3139346A1 (en) * 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
CN110592014A (zh) * 2019-08-14 2019-12-20 广东美赛尔细胞生物科技有限公司 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法
CN112430578A (zh) * 2019-08-26 2021-03-02 深圳宾德生物技术有限公司 携带安全开关并靶向Her2的嵌合抗原受体T细胞及其制备方法和应用
CN110863000B (zh) * 2019-11-22 2020-10-09 北京鼎成肽源生物技术有限公司 一种转染nk细胞的基因和转染载体
WO2021120526A1 (zh) * 2019-12-16 2021-06-24 四川大学华西医院 同时靶向间皮素和fap的双靶点嵌合抗原受体及其用途
MX2022007833A (es) * 2019-12-23 2022-09-23 Cellectis Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
CN115197990A (zh) * 2021-04-09 2022-10-18 中国科学院分子细胞科学卓越创新中心 基于细胞死活表型的信号通路激活剂和抑制剂的新型筛选系统
CN115197989A (zh) * 2021-04-09 2022-10-18 中国科学院分子细胞科学卓越创新中心 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统
CN113527515A (zh) * 2021-07-14 2021-10-22 南京蓝盾生物科技有限公司 一种靶向mesothelin的嵌合抗原受体及其应用
CN115873802A (zh) * 2021-09-29 2023-03-31 亘喜生物科技（上海）有限公司 嵌合抗原受体免疫细胞及其制法和应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140301993A1 (en) * 2011-10-28 2014-10-09 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
CN105330750A (zh) * 2015-11-20 2016-02-17 上海细胞治疗研究院 一种快速中止car-t细胞杀伤作用的分子刹车及其用途
CN106459989A (zh) * 2013-12-19 2017-02-22 诺华股份有限公司 人间皮素嵌合抗原受体及其用途
CN106480097A (zh) * 2016-10-13 2017-03-08 南京凯地生物科技有限公司 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
WO2017040945A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN106535925A (zh) * 2014-05-23 2017-03-22 佛罗里达大学研究基金会有限公司 基于car的免疫治疗
CN106543288A (zh) * 2016-10-24 2017-03-29 山东兴瑞生物科技有限公司 一种间皮素嵌合抗原受体修饰的t细胞制备及胰腺癌治疗上的应用
CN107058315A (zh) * 2016-12-08 2017-08-18 上海优卡迪生物医药科技有限公司 敲减人PD‑1的siRNA、重组表达CAR‑T载体及其构建方法和应用
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途
CN107207621A (zh) * 2015-02-24 2017-09-26 Ucl商务股份有限公司 嵌合蛋白

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378463B (es) * 2013-02-26 2025-03-10 Memorial Sloan Kettering Cancer Center Composiciones y usos de las mismas para inmunoterapia.
KR102466666B1 (ko) * 2013-03-15 2022-11-15 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140301993A1 (en) * 2011-10-28 2014-10-09 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
CN106459989A (zh) * 2013-12-19 2017-02-22 诺华股份有限公司 人间皮素嵌合抗原受体及其用途
CN106535925A (zh) * 2014-05-23 2017-03-22 佛罗里达大学研究基金会有限公司 基于car的免疫治疗
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途
CN107207621A (zh) * 2015-02-24 2017-09-26 Ucl商务股份有限公司 嵌合蛋白
WO2017040945A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN105330750A (zh) * 2015-11-20 2016-02-17 上海细胞治疗研究院 一种快速中止car-t细胞杀伤作用的分子刹车及其用途
CN106480097A (zh) * 2016-10-13 2017-03-08 南京凯地生物科技有限公司 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
CN106543288A (zh) * 2016-10-24 2017-03-29 山东兴瑞生物科技有限公司 一种间皮素嵌合抗原受体修饰的t细胞制备及胰腺癌治疗上的应用
CN107058315A (zh) * 2016-12-08 2017-08-18 上海优卡迪生物医药科技有限公司 敲减人PD‑1的siRNA、重组表达CAR‑T载体及其构建方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
权冰洁;韩双印;王春荣;: "基因修饰T细胞肿瘤过继免疫治疗安全性的研究进展" *
李津杞: "嵌合抗原受体修饰的T细胞治疗肿瘤的不良反应及相关治疗方案的研究进展" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116218914A (zh) * 2023-03-28 2023-06-06 武汉大学 一种构建肿瘤复发动物模型的方法

Also Published As

Publication number Publication date
CN109593721A (zh) 2019-04-09
CN109593721B (zh) 2022-11-01
WO2019063018A1 (zh) 2019-04-04

Similar Documents

Publication Publication Date Title
CN111133101B (zh) 可诱导分泌抗cd47抗体的工程化免疫细胞
CN111212903A (zh) 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
CN111051502B (zh) 通用型嵌合抗原受体t细胞制备技术
CN113784732B (zh) 靶向bcma的工程化免疫细胞及其用途
US11142581B2 (en) BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
CN114144430B (zh) Cd7-car-t细胞及其制备和应用
CN113784733A (zh) 靶向bcma的工程化免疫细胞及其用途
CN110157738B (zh) 靶向cd19和cd22的工程化免疫细胞及其应用
CN116997345A (zh) 靶向bcma的嵌合抗原受体
CN113330038A (zh) Cd20组合靶向的工程化免疫细胞
US20250186492A1 (en) Car-t cell targeting b7-h3 and application thereof in treatment of acute myeloid leukemia
CN109554349B (zh) Pd-1基因表达沉默的工程化免疫细胞
CN109897114B (zh) 具有自杀基因开关的靶向cd47的工程化免疫细胞
CN114686436A (zh) 一种靶向fshr和folr1双打靶点car t的制备及应用
CN114685683B (zh) 靶向gd2的car-t细胞及其制备和应用
CN110577932A (zh) 一种脐带血来源的嵌合抗原受体t细胞
US20230144447A1 (en) Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof
CN114685684A (zh) MUC1-Tn嵌合抗原受体修饰的Vγ9Vδ2T细胞及其应用
EP4357369A1 (en) Preparation and application of chimeric antigen receptor immune cell constructed on basis of granzyme b
CN110218702B (zh) 靶向cd138和cd19的免疫细胞组合及其应用
HK40062446A (zh) 靶向bcma的工程化免疫细胞及其用途
CN115572715A (zh) 一种靶向folr1和her2双打靶点car t的制备及应用
CN115491360A (zh) 一种靶向nkg2d配体和folr1双打靶点car t的制备及应用
CN119912579A (zh) 基于环肽Peptide G构建的嵌合抗原受体免疫细胞及其应用
HK40087789A (zh) 靶向cd22的嵌合抗原受体及其制法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200529

WD01 Invention patent application deemed withdrawn after publication